Premium
Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy
Author(s) -
Rice Lawrence,
Nichol Janet L.,
McMillan Robert,
Roskos Lorin K.,
Bacile Margaret
Publication year - 2001
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.1181
Subject(s) - medicine , megakaryocyte , thrombopoietin , immunology , thrombocytopenic purpura , growth factor , immune thrombocytopenia , platelet , antibody , immune system , romiplostim , receptor , biology , genetics , stem cell , haematopoiesis
We report a patient with cyclic thrombocytopenia and antiplatelet antibodies, a variant of chronic immune thrombocytopenic purpura (ITP), with a several year history of periodic fluctuation of the platelet count, megakaryocytic hyperplasia and high‐titer anti‐GPIb‐specific antiplatelet antibodies. The patient was resistant to multiple forms of therapy but has responded to the thrombopoietic growth factor, pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF). This case suggests that some patients with classic ITP may respond to thrombopoietic growth factors. Am. J. Hematol. 68:210–214, 2001. © 2001 Wiley‐Liss, Inc.